Principal Health Data Analyst, Craig Knott was first author on a poster entitled “First-line treatment patterns and overall survival of patients with advanced Merkel cell carcinoma (MCC) in England from 2013-2022: results of a nationwide observational cohort study” presented at ESMO Congress in Madrid back in October.  

Results from the nationwide cohort study (sponsored by Merck and previously conducted under an alliance between Merck and Pfizer) provide further real-world evidence for the clinical effectiveness of avelumab as a first-line treatment for patients with locally advanced (stage III) or metastatic (stage IV) MCC.

Great to see how work analysing data held by the NHS England National Disease Registration Service can provide validation for clinical trial data and previously presented observational studies. 

For further information please visit

Share This